On May 10, 2022 NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, reported that Matthew Seavey, Ph.D., MBA, NightHawk’s Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston (Press release, NightHawk Biosciences, MAY 10, 2022, View Source [SID1234614103]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be utilized to expand regulatory T-cell subsets for auto/inflammatory indications. PTX-35 is the Company’s first antibody-based product and is currently in a Phase 1 clinical trial for the treatment of patients with solid tumors.
Presentation Date/Time: Day-1, Wednesday, May 18th at 4:30 PM ET
Presentation Title: Agonizing Over Treg Expansion to Treat Human Disease: An Update on Our TNFRSF25-Agonist, PTX-35
Expert Panel Date/Time: Day-2, Thursday, May 19th at 11:30 AM ET
Expert Panel Title: Optimizing Routes of Administration & Delivery Mechanisms to Induce Timely Treg Specific Activation
Discussion Highlights:
Describing a clinical-stage Treg immunomodulator with utility in both oncology and auto/inflammation
Demonstrating preclinical efficacy in several possible, clinical indications including transplantation, autoimmunity, and metabolic diseases
Expanding plans for new indications and modalities, as well as opportunities for partnerships
The Hanson Wade 4th Annual Treg Directed Therapies Summit is focused on targeting and translating Treg modifying therapies and brings together executives and leading researchers from large pharma, biotech and academia to discuss developments in Treg therapies.